Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes
Transplantation of pancreatic islets for treating type 1 diabetes is restricted to patients with critical metabolic lability resulting from the need for immunosuppression and the shortage of donor organs. To overcome these barriers, we developed a strategy to macroencap-sulate islets from different...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
National Academy of Sciences (U.S.)
2018
|
Online Access: | http://hdl.handle.net/1721.1/115205 https://orcid.org/0000-0001-8777-9632 |
Summary: | Transplantation of pancreatic islets for treating type 1 diabetes is restricted to patients with critical metabolic lability resulting from the need for immunosuppression and the shortage of donor organs. To overcome these barriers, we developed a strategy to macroencap-sulate islets from different sources that allow their survival and function without immunosuppression. Here we report successful and safe transplantation of porcine islets with a bioartificial pancreas device in diabetic primates without any immune suppression. This strategy should lead to pioneering clinical trials with xenotransplantation for treatment of diabetes and, thereby, represents a previously unidentified approach to efficient cell replacement for a broad spectrum of endocrine disorders and other organ dysfunctions. Keywords: diabetes; porcine islets; beta-cell replacement; immune barrier |
---|